Butterfly Network, Inc.

Issued on behalf of VentriPoint Diagnostics Ltd.

VANCOUVER, BC, March 3, 2026 /CNW/ -- USANewsGroup.com News Commentary -- AI is making its way through the halls of our entire medical system, and the implementation is accelerating at a great pace. The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR^[1]. Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand cardiac platforms that prove economic value alongside clinical accuracy^[2]. Companies like VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Butterfly Network (NYSE: BFLY), Tempus AI (NASDAQ: TEM), RadNet (NASDAQ: RDNT), and GE HealthCare (NASDAQ: GEHC) are converting clinical validation into contracted hospital deployments.

Digital diagnostics platforms are projected to reach $7.67 billion by 2035 at an 18.12% CAGR as health systems shift from evaluating clinical capability to requiring department-level financial proof before adoption^[3]. Portable ultrasound, valued at $2.79 billion in 2026, is pushing cardiac assessment beyond traditional imaging labs and into point-of-care settings where speed and cost efficiency determine which technologies earn long-term hospital contracts^[4].

VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) recently signed a commercial agreement with LG Consulting Solutions to support deployment of its VMS+™ system across Northern California. Under the agreement, LG Consulting will provide economic analysis, clinical implementation support, and health system business case development to assist hospitals and cardiac programs in adopting VentriPoint's AI-enhanced echocardiography technology. The collaboration will focus on demonstrating the economic and clinical value of VMS+™ imaging and workflow integration across healthcare systems in the Sacramento and San Francisco regions.

As part of the agreement, LG Consulting Solutions is purchasing a VMS+™ system for deployment as a demonstration platform to support hospital engagement, clinician training, and economic value assessments. The agreement also includes the potential for revenue sharing related to 3D echocardiography processing services.

"Economic and operational clarity are critical to accelerating the adoption of new medical technologies," said Hugh MacNaught, President and CEO of VentriPoint Diagnostics. "This collaboration will help hospitals clearly evaluate how VMS+™ can improve cardiac care pathways, enhance clinical insight into cardiac function, and support better patient care while delivering measurable value to healthcare systems."

Northern California represents an important market for VentriPoint given its concentration of leading cardiac centers and healthcare systems focused on improving cardiovascular outcomes.

"Healthcare systems increasingly require clear clinical and economic evidence before adopting new technologies," said Lori Gallian, Principal of LG Consulting. "Through this collaboration, we will work directly with cardiac programs to develop practical implementation strategies and demonstrate how VMS+™ can deliver both clinical and operational benefits."

CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint 

In other industry developments and happenings in the market include:

Butterfly Network (NYSE: BFLY) recently reported fourth quarter 2025 revenue of $31.5 million, a 41% increase year-over-year, while generating positive operating cash flow for the first time in the company's history. Full-year 2025 revenue reached $97.6 million, up 19% from the prior year. The company also launched Compass, its AI-powered clinical decision support system designed to guide clinicians through point-of-care ultrasound exams.

" Nearly two years into our strategic plan, we are executing with financial discipline, strengthening our core point-of-care business, and now realizing material organic revenue from new initiatives," said Joseph DeVivo, CEO of Butterfly Network. "From expanding enterprise adoption in point-of-care, to building HomeCare into a commercial business, to enabling entirely new applications through Butterfly Embedded, it's all powered by the same proprietary Ultrasound-on-Chip™ technology. One platform and one diversified strategy that puts us in a strong position to execute and win."

The company issued 2026 revenue guidance of $117 million to $121 million, representing 20% to 24% growth. Butterfly's handheld ultrasound platform is used across emergency, primary care, and critical care settings, expanding cardiac and vascular assessment beyond traditional imaging labs.

Tempus AI (NASDAQ: TEM) recently reported fourth quarter 2025 revenue of $367.2 million, an 83% increase year-over-year. For the full year, Tempus generated $1.2 billion in revenue and issued 2026 guidance of approximately $1.59 billion with around $65 million in adjusted EBITDA, projecting its first year of positive adjusted profitability.

"In 2025, Tempus continued to set the standard for what it means to be a technology company operating in the healthcare space," said Eric Lefkofsky, Founder and CEO of Tempus. "The strength of our unit growth in diagnostics along with the accelerating growth of our data business is proof that we are unique in this space. As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years, but to also enhance the lives of millions of patients around the world."

The company's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatry. Tempus serves more than 50% of U.S. oncologists and is expanding its data licensing and clinical trial matching capabilities into cardiovascular diagnostics.

RadNet (NASDAQ: RDNT) recently acquired Gleamer, a Paris-based pioneer in AI-powered medical imaging, for up to €230 million. The acquisition positions RadNet's DeepHealth subsidiary as the largest radiology-focused clinical AI provider worldwide, combining Gleamer's BoneView and ChestView FDA-cleared algorithms with DeepHealth's existing suite of mammography, lung, and prostate AI solutions.

"As imaging volumes continue to rise amid an accelerating shortage of radiologists worldwide, reengineering high-volume workflows -- particularly routine imaging such as X-ray, ultrasound and mammography -- is becoming essential to sustaining access, efficiency and quality of care," said Dr. Howard Berger, President and CEO of RadNet. "For radiologists and providers, the key lies in advancing automated exam prioritization and draft reporting. The acquisition of Gleamer uniquely positions DeepHealth to expand its impact across routine imaging and high-impact acute diagnostic care and accelerate the delivery of automated diagnostics."

Gleamer's products are deployed in over 2,000 facilities across 30 countries. The combined entity is projected to generate approximately $30 million in annualized recurring AI revenue in 2026, with commercial deployment spanning bone fracture detection, chest pathology screening, and advanced mammography analytics.

GE HealthCare (NASDAQ: GEHC) recently announced the first implementation of its SIGNA Sprint Elite MRI system at Inova Health System. The platform integrates advanced cardiac imaging capabilities with AI-powered reconstruction technologies including AIR Recon DL and Sonic DL, designed to deliver diagnostic-quality cardiac MRI scans in significantly reduced timeframes.

"Achieving FDA clearance of our next-generation SIGNA MRI technology underscores our commitment to expanding access to high-quality imaging and elevating the standard of care for patients everywhere," said Kelly Londy, President and CEO, MR at GE HealthCare. "As MRI demand continues to rise across clinical areas, providers need solutions that deliver greater efficiency without compromising diagnostic precision. With this new SIGNA generation, we're redefining what's possible – aiming to bring smarter, faster, more sustainable and more consistent imaging to more patients, across more settings, with confidence."

The SIGNA Sprint Elite features a compact 22-square-meter footprint, allowing installation in outpatient and community settings previously limited to basic imaging. GE HealthCare's broader imaging portfolio serves more than 1 billion patients annually across 160 countries, with its MR division focused on expanding AI-integrated cardiac and neurological imaging platforms.

Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint 

CONTACT:

USA NEWS GROUP

info@usanewsgroup.com

(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. ("BAY") There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES:

1. https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-medical-imaging-market
2. https://www.precedenceresearch.com/echocardiography-market
3. https://www.towardshealthcare.com/insights/digital-diagnostics-system-market-sizing
4. https://www.towardshealthcare.com/insights/portable-ultrasound-market-sizing

Logo: https://mma.prnewswire.com/media/2838876/5833576/USA_News_Group_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/hospital-networks-turn-to-ai-enhanced-cardiac-imaging-to-cut-costs-and-improve-outcomes-302702775.html

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.

VANCOUVER, BC, Jan. 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – The global medical imaging market hit a massive $45.5 billion in 2026^[1], marking a total structural shift toward AI-native precision as advanced cancer therapies demand more intense heart monitoring than ever before^[2]. Hospitals are ditching expensive, bulky hardware for agile, cloud-based platforms that deliver MRI-quality results without the MRI-sized price tag. This pivot has catapulted the cardiac AI diagnostic sector to $2.22 billion this year^[3], driven by a desperate need for continuous imaging to catch heart dysfunction caused by cancer treatments^[4]. This high-stakes convergence positions VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Butterfly Network (NYSE: BFLY), RadNet (NASDAQ: RDNT), Nanox Imaging (NASDAQ: NNOX), and OneMedNet (NASDAQ: ONMD) as the essential engineering nodes where software-defined 3D modeling finally solves radiologist shortages.

Leading programs at institutions like the Mayo Clinic are proving that subscription-based imaging is the ultimate "cheat code" for patient care, turning diagnostic accuracy into measurable ROI through Device-as-a-Service frameworks^[5]. By using cloud-enabled solutions to manage complex heart risks, these companies are building high-margin, recurring revenue streams that align perfectly with the new world of value-based care. This isn't just a tech upgrade; it's a total reimagining of how the world tracks heart health for life.

Ventripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is building a subscription business around technology that converts standard 2D ultrasound images into detailed 3D heart models with MRI-level accuracy. The system delivers precise cardiac assessments at a fraction of the cost and complexity of traditional MRI imaging.

Strong investor demand recently doubled the company's private placement from $500,000 to $1 million. The capital will fund commercialization activities, manufacturing scale-up, regulatory submissions across additional markets, and operational requirements as the company transitions from development to revenue generation.

The latest strategic move focuses on proving economic value rather than just clinical capability. Ventripoint engaged Summit Sciences, a specialized healthcare consulting firm, to develop ROI models that show hospitals exactly what they will save. These models integrate real-world data to demonstrate measurable returns through process improvements, enhanced diagnostic accuracy, and optimized resource allocation.

"We are excited to partner with Dana and Summit Sciences to elevate our financial modeling capabilities," said Hugh MacNaught, President and CEO of Ventripoint Diagnostics. "Dana's extensive expertise in healthcare transformation, combined with Summit Sciences' proven track record in data-driven consulting, will enable us to deliver even more compelling value propositions to our customers. This initiative underscores our commitment to not only advancing cardiac care through technology but also ensuring that our solutions make strong economic sense for healthcare providers worldwide."

Dana Friesen leads Summit Sciences as CEO, bringing more than 15 years of experience in financial analysis and ROI optimization within the medical device sector. The firm has delivered billions in cumulative savings for clinical partners. Friesen's work with indigenous health networks aligns with Ventripoint's expansion into underserved markets.

The company announced a partnership with Nisga'a Valley Health Authority establishing a model for delivering advanced cardiac imaging to remote and Indigenous communities. The collaboration uses a hub-and-spoke design where local providers acquire ultrasound scans and transmit them digitally to specialists at a central hub for rapid interpretation.

Ventripoint appointed David Swetlow as Chief Financial Officer. Swetlow brings more than 15 years of senior management experience from high-growth medical technology companies including Sernova, Ondine, Protox, HealthPricer, and QLT. Management views the appointment as a key step in executing a commercial strategy designed to accelerate market adoption and drive revenue growth.

The company also issued a corporate update detailing its Device-as-a-Service subscription model. Management believes this approach shortens sales cycles and builds recurring revenue streams while making the technology accessible to more healthcare facilities without requiring large upfront capital investments.

CONTINUED… Read this and more news for VentriPoint Diagnostics at:  https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint

In other industry developments and happenings in the market include:

Butterfly Network (NYSE: BFLY) announced plans to release its Beam Steering API in first half 2026, marking the first time third-party developers will access digital 3D beam steering capabilities for AI-enabled ultrasound applications. The API leverages the company's proprietary semiconductor chip technology featuring approximately 9,000 elements that enable software-defined beam steering with off-axis tilt up to 20 degrees without mechanical motion.

"As the first to offer digital beam steering access to developers, Butterfly Network is changing the game for imaging AI, empowering more advanced tools that simplify image acquisition," said Steve Cashman, Chief Business Officer of Butterfly Network. "As our platform evolves, Butterfly partners gain access to more of our core imaging capabilities, allowing them to build richer, more sophisticated applications."

The planned SDK access will support advanced imaging workflows across multiple presets including abdominal, cardiac, obstetric, musculoskeletal, vascular, and lung imaging. Butterfly Network continues expanding its Butterfly Garden and Ultrasound-on-Chip co-development programs, with availability and technical details dependent on ongoing development, regulatory considerations, and partner agreements to democratize ultrasound technology across clinical settings.

RadNet (NASDAQ: RDNT) has acquired Radiology Regional, a division of LucidHealth serving Southwest Florida, expanding RadNet's footprint to 13 locations across Naples, Cape Coral, Fort Myers, Port Charlotte and Sarasota. The acquisition adds approximately 400 employees and 44 contracted radiologists to RadNet's operations, with the transaction projected to contribute approximately $100 million in revenue during 2026.

"RadNet is proud to enter a dynamic region of Florida and build on Radiology Regional's well-trusted history," said Steve Forthuber, President and CEO of Eastern Operations for RadNet. "Through our clinical excellence, operations expertise and AI-powered digital health solutions, RadNet intends to bring accessible and affordable leading-edge patient care, population health screening programs and a focus on early detection of disease to the communities of Southwest Florida."

The 13 acquired centers provide comprehensive multi-modality imaging including MRI, CT, PET/CT, mammography, ultrasound and X-ray services built over Radiology Regional's half-century history. RadNet plans to deploy its DeepHealth AI-powered innovations across the acquired facilities to increase clinical accuracy, streamline imaging processes and improve patient experience in the rapidly growing Southwest Florida market.

Nanox Imaging (NASDAQ: NNOX) has expanded operations across Serbia, Montenegro, and Bosnia and Herzegovina through a strategic collaboration with Adriamed d.o.o. Beograd, a Belgrade-based medical device distributor. The engagement brings the Nanox.ARC multi-source digital tomosynthesis system to healthcare providers throughout the Western Balkans region.

"We are building momentum in Europe through this strategic collaboration with Adriamed, whose expertise and regional reach will support our commercial expansion in the Western Balkans," said Erez Meltzer, CEO and Acting Chairman of Nanox Imaging. "Our strategy centers on expanding access to cost-effective imaging solutions through established regional partners."

Under the agreement, Adriamed becomes Nanox Imaging's exclusive partner for the Nanox.ARC system and related services across the three-country region. The collaboration follows recent distribution agreements in Greece, Romania, Czech Republic and France as Nanox Imaging continues building its European commercial footprint.

OneMedNet (NASDAQ: ONMD) has supported FDA 510(k) clearance of mlHealth 360's Scaida BrainCT-ICH, an AI-powered software solution for rapid detection of intracranial hemorrhage from head CT scans. OneMedNet's regulatory-grade Real-World Data spanning longitudinal electronic medical records, diagnostic imaging, and clinical reports played a critical role in supporting model development, validation, and regulatory submission for the software that analyzes head CT images in approximately 5.97 seconds.

"We are proud to collaborate with our premier partner mlHealth 360 and to support their efforts in advancing patient care through clinically impactful AI," said Aaron Green, CEO and President of OneMedNet. "Seeing OneMedNet's regulatory-grade Real-World Data--enriched with medical imaging and EMR context--contribute directly to an FDA-cleared solution reinforces the value of high-quality data in accelerating meaningful innovation."

This milestone validates OneMedNet's position as a leading Real-World Data provider as life science and AI companies increasingly rely on OneMedNet to support FDA submissions. The depth, diversity, and quality of OneMedNet's curated imaging and clinical datasets enabled mlHealth 360 to access fit-for-purpose data while maintaining data integrity and regulatory compliance.

Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint

CONTACT:

USA NEWS GROUP

info@usanewsgroup.com

(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. ("BAY") There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES:

1.   https://www.grandviewresearch.com/industry-analysis/medical-imaging-systems-market

2.   https://www.bloomberg.com/news/articles/2026-01-23/new-potent-cancer-treatments-are-raising-heart-risks-for-survivors

3.   https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-report

4.   https://www.jacc.org/doi/10.1016/j.jaccao.2025.08.001

5.   https://link.springer.com/article/10.1186/s40959-016-0014-2

Logo - https://mma.prnewswire.com/media/2838876/5737507/USA_News_Group_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-medical-imaging-revolution-software-native-tech-disrupts-45b-market-302671377.html